Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nucleis Radiopharmaceuticals
Liège, Belgiumnucleis.eu ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Nucleis was a Belgian GMP-certified CDMO and manufacturer specializing in radiopharmaceuticals focused on PET diagnostics, offering tracer manufacturing and distribution across Benelux, France, Germany, Luxembourg, and the Netherlands. After its April 2025 acquisition by Curium, it expanded capabilities in oncology, neurology, and cardiology PET tracers.
- Therapeutic areas
- OncologyNeurologyCardiovascular
- Modalities
- RadiopharmaceuticalPET tracers
- Industry
- Contract Manufacturing Organization
02
Partnerships
University of LiègeCyclotron Research Centre
Beyond the preview
Go deeper on Nucleis Radiopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nucleis Radiopharmaceuticals.